DPP4 and diabetes mellitus: Use of DPP-4 inhibitors has been associated with an increased risk of inflammatory bowel disease compared with other diabetes drugs (53.4 vs. 34.5 per 100,000 person-years, HR 1.75, 95% CI 1.22–2.49) in a population-based study [107].